Journals / Turkish Journal of Anaesthesiology and Reanimation / 2015 / Cilt: 43 - Sayı: 5

Ullrich Hastalığı Olan Bir Hastada Anestezi İdamesi ve Sugammadeks Kullanımı

Anaesthesia Management and Use of Sugammadex in a Patient with Ullrich’s Disease

Pages
356–359
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, we suggest that the use of propofol infusion to avoid the use of inhalation anaesthetics and the use of sugammadex for the reversal of the effects of rocuronium is safe in patients with Ullrich’s disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Here, we report anaesthesia management and the successful use of total intravenous anaesthesia and sugammadex in a patient with Ullrich’s disease.
📊
Key Findings & Data:After the end of the surgery, when the train-of-four value was 0%, 4 mg kg−1 sugammadex was administered, and the patient was successfully extubated after 36 s.
💡
Conclusion & Impact:In conclusion, we suggest that the use of propofol infusion to avoid the use of inhalation anaesthetics and the use of sugammadex for the reversal of the effects of rocuronium is safe in patients with Ullrich’s disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Here, we report anaesthesia management and the successful use of total intravenous anaesthesia and sugammadex in a patient with Ullrich’s disease. Propofol and remifentanyl infusion was used for anaesthesia. After the end of the surgery, when the train-of-four value was 0%, 4 mg kg−1 sugammadex was administered, and the patient was successfully extubated after 36 s. No adverse effects or safety concerns were observed. In conclusion, we suggest that the use of propofol infusion to avoid the use of inhalation anaesthetics and the use of sugammadex for the reversal of the effects of rocuronium is safe in patients with Ullrich’s disease.

Özet

Bu olgu sunumuzda Ullrich hastalığı olan bir hastada başarılı to- tal intravenöz anestezi ve sugammadeks kullanımını bildirmeyi amaçladık. Anestezi idamesi için propofol ve remifentanil infüz- yonu kullanıldı. Cerrahi bitiminde train of four (TOF) değerleri %0 iken, 4 mg kg-1 sugammadeks verildi ve 36. saniyede hasta başarıyla ekstübe edildi. Herhangi bir yan etki ile karşılaşılmadı. Sonuç olarak, Ullrich hastalığı olan hastalarda inhalasyon aneste- tiklerinin kullanılmasından kaçınmak adına propofol infüzyonun kullanımının ve roküronyumun etkilerinin sonlandırılması için sugammadeks kullanımının güvenli olduğunu bildirmekteyiz

🔖

Cite This Article

ERBABACAN, Ş. E., KÖKSAL, G. M., ŞEKER, T. B., EKİCİ, B., ÖZCAN, R., ALTINDAŞ, F. (2015). Ullrich Hastalığı Olan Bir Hastada Anestezi İdamesi ve Sugammadeks Kullanımı. Turkish Journal of Anaesthesiology and Reanimation, Cilt: 43 - Sayı: 5, 356–359. https://ajindex.com/articles/370325

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Reed UC. Congenital muscular dystrophy Part II: A review of pathogenesis and therapeutic perspectives. Arq Neuropsiquiatr 2009
  2. [CrossRef] 2. Voermans NC, Bonnemann CG, Hamel BC, Jungbluth H, van Engelen BG. Joint hypermobility as a distinctive feature in the differential diagnosis of myopathies. J Neurol 2009
  3. [CrossRef] 3. Nalini A, Gayathri N, Santosh V. Ullrich congenital muscular dystrophy: report of nine cases from India. Neurol India 2009
  4. [CrossRef] 4. Ustun YB, Sarihasan B, Kocamanoglu IS, Yegin S, Azar H. Use of sugammadex in myesthenia gravis and becker muscular dystrophy: Four cases. J Neurol Sci Turk 2012
  5. Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg 2007
  6. [CrossRef] 6. Grosu I, Truong D, Teodorescu S, Mousny M, Veyckemans F. Anesthetic management of a child with Ullrich myopathy. J Anesth 2012
  7. [CrossRef] 7. Voit T. Congenital muscular dystrophies. In: Karpati G, Hilton-Jones D, Griggs RC, (eds). Disorders of voluntary muscle. 7th ed.Cambridge, UK: Press Syndicate of the University of Cambridge 2001: 503-24. 8. McKenzie AJ, Couchman KG, Pollock N. Propofol is a ‘safe’ anaesthetic agent in malignant hyperthermia susceptible patients. Anaesth Intensive Care 1992
  8. Puangsuvan N, Mester RA, Ramachandran V, Tobias JD. Perioperative care of a child with Ullrich congenital muscular dystrophy. Middle East J Anesthesiol 2009
  9. Li G, Brady JE, Rosenberg H, Sun LS. Excess comorbidities associated with malignant hyperthermia diagnosis in pediatric hospital discharge records. Paediatr Anaesth 2011
  10. [CrossRef] 11. Matsuki Y, Hirose M, Tabata M, Nobukawa Y, Shigemi K. The use of sugammadex in a patient with myotonic dystrophy. Eur J Anaesthesiol 2011
  11. [CrossRef] 12. Plaud B, Meretoja O, Hofmockel R, Raft J, Stoddart PA, van Kuijk JH, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology 2009
  12. [CrossRef] 13. Della Rocca G, Di Marco P, Beretta L, De Gaudio AR, Ori C, Mastronardi P. Do we need to use sugammadex at the end of a general anesthesia to reverse the action of neuromuscular bloking agents? Minerva Anestesiol 2013
  13. de Boer HD, van Esmond J, Booij LH, Driessen JJ. Reversal o